Waddell & Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Waddell & Associates’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$613K	Buy	+1,235	New	+$547K	0.03%	222

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

Asset Management One Tokyo, Japan $39B AUM 37.51% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Waddell & Associates's VRTX Position: Q2 2026 in Review

Waddell & Associates opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 1,235 shares worth $613K. The stake represents 0.03% of the portfolio and ranks #222 among its holdings.

564 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Waddell & Associates held 1,235 shares of Vertex Pharmaceuticals worth $613K as of Q2 2026.
Vertex Pharmaceuticals was a new Waddell & Associates position in Q2 2026.
Vertex Pharmaceuticals made up 0.03% of Waddell & Associates's portfolio in Q2 2026, its #222 holding.
564 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Waddell & Associates's 13F filing for Q2 2026, filed 15 Jul 2026.